Article: Amplification: Neurochem's Alzhemed.(Correction Notice)

Article: CORRECTION FROM SOURCE: CBp Carbon Industries Reports on Major ...
Canadian Corporate News;  March 5, 2009 ;     700+ words ... ... TM) is marketing at about $1.00US per pound or US$2200 per tonne. CYPRUS COMMERCIAL PLANT. CBp's first generation phase III commercial production facility, located in Limasol, Cyprus, is completing final equipment installation. The plant is slated ...

Article: Corrections & Clarifications.(Correction notice)
BIOWORLD Today;  March 17, 2008 ;     336 words ... ... that NeurogesX's NGX-4010 failed one of three Phase III trials in postherpetic neuralgia. The drug has met its endpoints in two Phase III postherpetic neuralgia trials, and one Phase III trial for peripheral neuropathic pain in patients ...

Article: /C O R R E C T I O N -- CYTOGEN/(Correction Notice)
PR Newswire;  April 25, 1996 ;     700+ words ... ... meetings. Results from the first Quadramet Phase III clinical trial will be presented for ... and data from Quadramet's second Phase III trial will be presented at this year ... with the most advanced treatment in late Phase III development for renal cell carcinoma ...

Article: /C O R R E C T I O N -- CEPHALON/(Correction ...
PR Newswire;  February 12, 1996 ;     361 words ...In NYM033, Cephalon Announces Modafinil Phase III Trial Results, moved earlier today, the first graph, third line, should read "first of two Phase III clinical trials" rather than "Phase II" as incorrectly transmitted by PR Newswire ...

Article: AIDS Weekly May 27, 2002, Headline Error.(Correction to May 27, ...
AIDS Weekly;  July 8, 2002 ;     551 words ... ... 2002. The correction should have read: A headline appearing in the May 27 issue of AIDS Weekly incorrectly stated that phase III results of vaccine candidates were expected within a month. The results are expected within a year, according to researchers ...

Article: Correction.(Correction notice)
BIOWORLD Today;  February 2, 2007 ;     386 words ...A story in the Feb. 1 issue of BioWorld Today should have said Palatin Technologies Inc. expects to begin Phase III trials of bremelanotide in erectile dysfunction in the first half of this year. Editor's Note: The correction will be made in BioWorld Online.

Article: CORRECTION.(Correction Notice)
BIOWORLD Today;  October 4, 2004 ;     336 words ... ... Pharmaceuticals Inc.'s anidulafungin, indicating that the company could achieve approval upon completion of an ongoing Phase III trial to treat invasive candidiasis/candidemia or the completion of further clinical work in patients with candidal disease ...